TG Therapeutics Raises 2024 Revenue Guidance Amid Soaring BRIUMVI Sales
TG Therapeutics' Q2 2024 results show BRIUMVI sales at $72.6M, prompting a revenue guidance raise to $290-$300M.
- Latest
- Trending
TG Therapeutics' Q2 2024 results show BRIUMVI sales at $72.6M, prompting a revenue guidance raise to $290-$300M.
Iovance Biotherapeutics has the potential to become a multiproduct company, and even if its stock doesn't soar quickly, it's still ...
Lazard Asset Management and Coppell Advisory Solutions both acquired stakes in Legend Biotech. The company's stock performance had a low ...
Adicet Bio receives an upgrade from Jones Trading, raising its rating to Buy with a new price target of $6.00. ...
Goldman Sachs Asset Management launches a $650M life sciences fund, focusing on growth-oriented private equity investments in early- to mid-stage ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.